



LMA International NV

25 February 2008

Announcement to the Singapore Exchange

**LMA TO APPEAL DECISION OF EUROPEAN PATENT OFFICE TO
REVOKE PATENT**

- **Provides further details**

Mainboard-listed LMA International NV (“LMA” or the “Company”), the global leader in the development and marketing of the LMA™ range of supraglottic airways, would like to provide further information on the effects of the decision by the European Patent Office (“EPO”) on the Company. This follows the announcement made to the Singapore Exchange on Friday 22 February 2008 on its ongoing legal proceedings against Ambu A/S (“Ambu”) in Europe.

The Company's European Distal Rib Patent EP 1119386 relates to a specific feature of supraglottic airway devices and forms a very small part of the almost 200 granted patents in the Company's extensive patent portfolio covering 25 airway management inventions.

The revocation of this patent applies only to Europe which, excluding Germany, accounts for less than 20% of the Company's total sales. LMA expects the EPO decision to have little or no impact on the Company's financial performance for FY2008.

As reported earlier, the EPO decision does not affect LMA's patent infringement proceedings against Ambu in the United States, nor is it expected to affect its existing damage claim for Ambu's infringement of its German utility model in Germany.

The EPO decision, however, is expected to further delay the Company's infringement action against Ambu in the Netherlands and in France, pending the outcome of its appeal against the EPO decision to be filed.

Because the EPO decision was not on the merits but on a technicality, LMA is confident of succeeding in its appeal and the reinstatement of its patent EP 1119386.

LMA International NV

Osprey House, Old Street, St. Helier, Jersey JE2 3RG, Channel Islands

ENDS

NOTES:

LMA International NV

Incorporated in the Netherlands Antilles in 1998, LMA was listed on the Singapore Exchange in March 2005. LMA designs, develops, markets and distributes medical equipment, principally the LMA™ range of supraglottic airway management devices. These devices are used by physicians to allow respiration, provide ventilation to, and support the airway of patients undergoing surgical procedures and life-saving interventions. Since its first product, the LMA Classic™, was approved by the FDA for use in the United States in 1991, LMA's growth has been driven by the development of innovative products, geographic expansion, and increased customer awareness of the LMA™ airway as an alternative airway management device. LMA has established a leading position in this growing market.

LMA has an office in Jersey, Channel Islands, and subsidiaries in Singapore, Germany and San Diego, California. Through its 50 percent joint venture in LMA Urology Limited, the Group has a subsidiary in Switzerland to design, manufacture and distribute the LMA StoneBreaker™. DBS Bank and Credit Suisse were the Joint Global Coordinators and Joint Bookrunners for the Initial Public Offering of shares in LMA.

LMA™ Airways

For over 20 years, The Laryngeal Mask Company Limited has been making advances in airway design and technology which have impacted directly on patient safety and comfort. British anaesthetist Dr Archie Brain designed the first LMA™ airway in 1988. Since then, LMA™ airways have been used over 200 million times around the world and are supported by over 2,500 published references. The LMA™ airway has become the most well-known and respected supraglottic airway device worldwide, with a full range of products designed for specialist clinical needs including routine anaesthesia, PPV, ENT surgery, the difficult airway and emergency situations.

LMA Patent Portfolio

LMA has an extensive patent portfolio that protects the key products in the LMA™ range, as well as new products currently under development. The Company's portfolio comprises an estimated 335 granted and pending patents worldwide, the majority of which have a significant unexpired term. Of the Company's granted patents, the earliest expiry date is 2008, and the latest is around 2025.